abstract: In a prospective randomized short-term study, the efficacy and safety of @entity19619 and a combination of @entity1482 and @entity1483 were compared in the treatment of hepatic cirrhotic @entity843 . Twenty-two @entity1 were randomized to either @entity19619 , 20 mg/day (group I), or @entity1482 , 200 mg/day, combined with @entity1483 , 40 mg on alternate days (group II). During the first 4 days of treatment, adequate diuresis, measured as loss of body weight greater than 1.6 kg, occurred in 7 @entity1 in group I and in 3 in group II. In the latter group, another 4 @entity1 responded satisfactorily after a further 4 days of treatment. Four @entity1 in group I who failed to respond to @entity19619 with an adequate loss of body weight were subsequently treated with the @entity1482 - @entity1483 combination, but only one responded. Two @entity1 in group II who failed to respond to the combination of @entity1482 and @entity1483 also failed to respond to @entity19619 . In both groups, a positive diuretic response occurred only when the pretreatment fractional @entity1372 excretion exceeded 0.2%. Diuretic resistance was overcome only by additional treatments which reduced proximal tubular @entity1372 reabsorption. @entity19619 commonly induced hypokalaemia; in contrast hyperkalaemia was seen following treatment with the @entity1482 - @entity1483 combination. Renal function remained stable in all @entity1 during both diuretic treatments. An open ongoing 6-month trial of @entity6955 , 10-40 mg/day, in combination with @entity1482 , 50-400 mg/day, has also been undertaken in 117 @entity1 with cirrhotic @entity843 who showed inadequate responses to salt and water restriction and @entity1482 alone. Twenty-seven @entity1 have been withdrawn from the study, 9 for the complications of @entity5693 , @entity548 oesophageal varices, or hyponatraemia. Twenty-two @entity1 are still being treated and 68 have completed the trial on a mean dose of @entity6955 , 15 mg/day. Body weight was reduced by a mean of 2.3 kg at 6 weeks, 2.6 kg at 14 weeks and 3.2 kg after 6 months. Loss of body weight was primarily associated with @entity843 and secondarily with reduction of peripheral @entity4 . There were no untoward adverse reactions with @entity6955 , and no significant changes in serum electrolytes, liver, renal, or haematological variables.

title: Liver cirrhosis with @entity843 : pathogenesis of resistance to diuretics and long-term efficacy and safety of XXXX .

entities_list: @entity5693 :: ('MESH:D006501', 'Disease') :: ['hepatic coma']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema']

entities_list: @entity843 :: ('MESH:D001201', 'Disease') :: ['ascites', 'reduction of ascites']

entities_list: @entity19619 :: ('MESH:D014988', 'Chemical') :: ['xipamide', 'Xipamide']

entities_list: @entity1483 :: ('MESH:D005665', 'Chemical') :: ['furosemide']

entities_list: @entity6955 :: ('MESH:C026116', 'Chemical') :: ['torasemide']

entities_list: @entity1482 :: ('MESH:D013148', 'Chemical') :: ['spironolactone']

answer: @entity6955 :: (MESH:C026116,Chemical) :: ['torasemide']


abstract: PURPOSE: We compared saline, @entity228 , and autologous blood injections for @entity2633 in a prospective, blinded, randomized, controlled trial. The null hypothesis was that @entity1 -rated outcomes after autologous blood injection would not be superior to @entity228 and saline injections. METHODS: @entity1 with clinically diagnosed @entity2633 of less than 6 months' duration were randomized into 1 of 3 groups to receive a 3-mL injection of saline and @entity3303 , @entity228 and @entity3303 , or autologous blood and @entity3303 . Of 34 subjects who enrolled, 28 completed follow-up. A total of 10 were randomized to the saline group, 9 to the autologous blood group, and 9 to the @entity134 group. Every @entity1 had 3 mL blood drawn, and the injection syringe was foil-covered to prevent the subject from knowing the contents. The primary outcome measure was the Disabilities of the Arm, Shoulder, and Hand (DASH) score. @entity1 completed a @entity158 visual analog scale, DASH, and the @entity1 -Rated Forearm Evaluation before injection and at 2 weeks, 2 months, and 6 months after injection. We performed statistical analysis using repeated measures of analyses of variance. RESULTS: There were no significant differences in DASH scores among the 3 groups at 2- and 6-month follow-up points, with the mean scores for saline at 20 and 10, respectively, compared with 28 and 20 for autologous blood and 28 and 13 for @entity134 injections. Secondary measures showed similar findings, with outcomes scores showing improvement in all 3 groups. CONCLUSIONS: In this prospective, randomized, controlled trial, autologous blood, @entity228 , and saline injection provide no advantage over placebo saline injections in the treatment of @entity2633 . @entity1 within each injection group demonstrated improved outcome scores over a 6-month period.

title: Comparison of autologous blood, @entity228 , and saline injection in the treatment of XXXX : a prospective, randomized, controlled multicenter study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'participant', 'patient', 'Patient']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity2633 :: ('MESH:D013716', 'Disease') :: ['lateral epicondylitis']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

answer: @entity2633 :: (MESH:D013716,Disease) :: ['lateral epicondylitis']


abstract: A case of rarely occurring @entity1494 in a @entity1 of 2 is presented. The period from the first clinical manifestations ( @entity4658 , macrohematuria) to @entity204 was 4 months. Urological examinations were done at the period of manifest clinical signs of disuria. A @entity5 of the urinary bladder almost completely filling the lumen was found in the form of numerous papillary-polyplike formations, with @entity74 . On the materials of operation biopsy the histological conclusion of urinary bladder @entity980 was reached. The @entity204 occurred with @entity281 and manifestations of drug @entity3028 (cytostatic therapy). The @entity5 outgrew into the posterior wall, no @entity3 were found. Histologically the @entity5 was characterized by random arrangement of mono- and multinuclear polymorphic cells with oxiphilic cytoplasm. The granularity and fibrous pattern of the cytoplasm were discernible. Typically, an argirophilic framework was observed. By its histological structure the @entity5 belongs to the embryonal type.

title: [ XXXX of the bladder in a 2-year-old @entity1 ].

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['rhabdomyosarcoma of the urinary bladder']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity3028 :: ('MESH:D000380', 'Disease') :: ['agranulocytosis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['urogenic infection']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['uropassage disorders']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity980 :: ('MESH:D012208', 'Disease') :: ['rhabdomyosarcoma']

answer: @entity980 :: (MESH:D012208,Disease) :: ['Rhabdomyosarcoma']


abstract: BACKGROUND: @entity339 ( @entity339 ) is a severe condition which may be best treated by surgery, notwithstanding a relatively high mortality rate. OBJECTIVES: To evaluate the results of mitral valve replacement or repair in @entity1 with @entity339 . @entity1 AND METHODS: Retrospective review of the clinical records in 29 @entity1 with @entity339 who were surgically treated from 1990 to 1999. They represent 8% of surgical procedures on the mitral valve. RESULTS: Mean age was 67 +/- 9 years. Surgery was performed urgently in 19 @entity1 (66.5%). NYHA functional class was 3.4 +/- 0.8. The mechanism of @entity339 was annular dilatation and spreading of papillary muscles in 18 @entity1 , @entity121 in 9 and @entity82 in 2. Mitral valve replacement was performed in 14 @entity1 and mitral valve repair in 15. Twenty four @entity1 (83%) had concomitant myocardial revascularization. Overall surgical mortality was 24%; 26% for mitral replacement and 13% for mitral valve repair (p = 0.215). On follow up of 26 +/- 33 months, one year survival was 76 +/- 0.8% and 5 years survival was 59 +/- 12%. Excluding in hospital mortality, survival was 100% at one year and 78 +/- 14% at 5 years. Functional class improved in all survivors, to 1.4 +/- 0.5. Late echocardiographic evaluation of @entity1 with mitral valve repair showed absence of @entity339 in 58%, 1+ MR in 17% and 2+ MR in 25%. CONCLUSION: In spite of a high perioperative mortality, surgery for @entity339 is a valuable procedure for @entity1 with an otherwise highly lethal disease.

title: [Surgery for XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity339 :: ('MESH:D008944', 'Disease') :: ['Ischemic mitral regurgitation', 'mitral regurgitation', 'IMR']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['papillary muscle rupture']

answer: @entity339 :: (MESH:D008944,Disease) :: ['mitral valve insufficiency']


abstract: A 54-year-old male visited a local physician with right dorsolumbar pain as the chief complaint. Ultrasonography revealed a @entity5 mass 13 cm in diameter at the lower part of the liver, and the @entity1 was referred to our hospital. On abdominal computed tomography, uneven contrast-enhanced effects were recognized in the @entity5 . On magnetic rescmance imaging studies, T1-weighted images showed a hypoechoic pattern from the kidney and a weak hyperechoic pattern from the muscle. T2-weighted images showed uneven hyperecoic patterns. Uneven contrast-enhanced effects were recognized inside and on the margin of the @entity5 . A diagnosis of retroperitoneal @entity5 was made, and surgery was performed. Histopathological examination revealed a fascicular alignment of spindle cells in the area in which the myxoid matrix is seen. On the immunological special test, only @entity2277 was positive, which led to the diagnosis of @entity1492 . @entity1492 originating from retroperitoneal @entity5 is relatively rare.

title: [Retroperitoneal XXXX with myxoid matrix: a case report].

entities_list: @entity1492 :: ('MESH:D005354', 'Disease') :: ['Fibrosarcoma', 'fibrosarcoma']

answer: @entity1492 :: (MESH:D005354,Disease) :: ['fibrosarcoma']


abstract: PURPOSE: To determine the maximal tolerated dose (MTD) of the combination of weekly @entity13850 and every other week @entity1206 in @entity1 with advanced or refractory solid @entity5 . METHODS: @entity1 were treated with intravenous @entity13850 on days 1, 8, 15, and 22 and intravenous @entity1206 on days 1 and 15. Cycles were repeated every 28  days. RESULTS: Nineteen @entity1 were enrolled in the study. Tumor types included lung (5), prostate (2), neuroendocrine of pancreas (1), bladder (2), uterus (3), cervix (4), and vagina (2). All @entity1 had received prior chemotherapy. Four @entity1 were enrolled to dose level I, nine to dose level II, and six to dose level III. Six @entity1 were inevaluable and replaced. Fifty-seven total cycles were administered. There was 1 dose-limiting @entity137 at level II (grade 3 @entity448 / @entity2700 ) and 2 at level III (grade 3 @entity1371 ; grade 4 @entity1398 ). Two @entity1 died at dose level III; one was study-related with grade 4 @entity1398 . Grade 3/4 @entity137 observed during the first cycle included @entity1398 (2), @entity417 (1), @entity448 (1), @entity2700 (1), @entity4854 (1), @entity2298 (1), and @entity1371 (1). Best response included two @entity1 (prostate and @entity1149 ) with partial response and eight @entity1 with stable disease with median duration of best response of 3.2  months. CONCLUSIONS: @entity13850 25  mg given days 1, 8, 15, and 22 in combination with @entity1206 20  mg/m(2) given days 1 and 15 every 4  weeks was found to be the MTD. This dose combination is considered feasible in phase II trials.

title: Phase I clinical trial of XXXX and @entity1206 in advanced solid @entity5 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity13850 :: ('MESH:C401859', 'Chemical') :: ['temsirolimus', 'Temsirolimus']

entities_list: @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity2700 :: ('MESH:D003681', 'Disease') :: ['dehydration']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer']

entities_list: @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia']

entities_list: @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity1371 :: ('MESH:D007008', 'Disease') :: ['hypokalemia']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

answer: @entity13850 :: (MESH:C401859,Chemical) :: ['temsirolimus']


abstract: Left ventricular (LV) chamber and myocardial wall compliance were investigated in @entity35 with exercise-induced @entity1283 . Voluntary exercise training was performed on running wheels. After 16 wk of exercise training, cardiac performance was measured in anesthetized open-chest ventilated @entity35 . LV end-diastolic performance was calculated from both short-axis external diameter and long-axis segmental length measurements. Exercise-trained @entity35 developed significant @entity4346 (1.03 +/- 0.02 g) compared with control @entity35 (0.91 +/- 0.03 g; P < 0.01). The physiological @entity1184 was associated with an increased LV wall thickness-to-internal radius ratio consistent with a concentric geometry. LV end-diastolic stiffness (slope of the linearized LV end-diastolic pressure-strain relationship) was decreased in both the short (P < 0.02) and long (P < 0.02) axis of LV as a result of exercise training. The LV end-diastolic chamber stiffness (slope of the linearized LV end-diastolic pressure-volume relationship) was also decreased in the exercised group (P < 0.05). The decreased chamber stiffness occurred as a consequence of a decrease in the regional myocardial wall elastic stiffness (slope of the linearized LV end-diastolic stress-strain relationship; P < 0.05). Thus an increased LV wall thickness as a result of exercise-induced @entity4346 is associated with an enhanced ventricular chamber compliance, which in turn is attributed to a decrease in the diastolic stiffness of the myocardial wall.

title: Exercise-induced XXXX is associated with an increased myocardial compliance.

entities_list: @entity1283 :: ('MESH:D006332', 'Disease') :: ['cardiac hypertrophy']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy']

entities_list: @entity4346 :: ('MESH:D017379', 'Disease') :: ['LV hypertrophy']

answer: @entity1283 :: (MESH:D006332,Disease) :: ['cardiac hypertrophy']


abstract: @entity13834 has been successfully applied in the fight against phytopathogenic fungi. Here, the putative antifungal effect of this pseudooligosaccharide against the prevalent @entity1 pathogen @entity5132 was examined. @entity13834 acts as a potent competitive inhibitor of the cell-wall-linked acid trehalase (Atc1p). The estimated MIC50 for the @entity5132 parental strain CEY.1 was 500 mg/l. The addition of doses below MIC50 to exponentially growing CEY.1 cells caused a slight reduction in cell growth. A concentration of 1 mg/ml was required to achieve a significant degree of cell killing. The compound was stable as evidenced by the increased reduction of cell growth with increasing incubation time. A homozygous atc1delta/atc1delta mutant lacking functional Atc1p activity showed greater resistance to the drug. The antifungal power of @entity13834 was limited compared with the drastic lethal action caused by exposure to @entity2379 . The endogenous content of @entity7970 rose significantly upon @entity13835 and @entity2379 addition. Neither serum-induced hypha formation nor the level of myceliation recorded in macroscopic colonies were affected by exposure to @entity13834 . Our results suggest that, although @entity13834 cannot be considered a clinically useful antifungal against @entity5132 , its mechanism of action and antifungal properties provide the basis for designing new, clinically interesting, antifungal-related compounds.

title: Analysis of XXXX as a potential antifungal compound against @entity5132 .

entities_list: @entity7970 :: ('MESH:D014199', 'Chemical') :: ['trehalose']

entities_list: @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B']

entities_list: @entity5132 :: ('5476', 'Species') :: ['Candida albicans', 'C. albicans']

entities_list: @entity13834 :: ('MESH:C030790', 'Chemical') :: ['Validamycin A', 'validamycin A']

entities_list: @entity13835 :: ('MESH:C003749', 'Chemical') :: ['validamycin']

answer: @entity13835 :: (MESH:C003749,Chemical) :: ['validamycin']


abstract: We have studied biochemical and behavioral effects of chronic @entity2819 administration in two inbred @entity35 stains (Fischer 344 and Lewis), known to differ in their @entity2339 and in their behavioral responses to drugs of abuse. First, we studied @entity2819 regulation of phosphoproteins in the ventral tegmental area of sham- and @entity2819 -treated Fischer and Lewis @entity35 , by means of back-phosphorylation and two-dimensional gel electrophoresis and Western blotting analysis. @entity2819 administration upregulated @entity669 hydroxylase immunoreactivity and decreased glial-fibrillary acidic protein phosphorylation state in the ventral tegmental area of Fischer @entity35 only, with no changes seen in Lewis @entity35 . We also studied @entity2819 effects on locomotor sensitization to @entity2072 , a behavior known to be regulated by the ventral tegmental area. In Fischer @entity35 , chronic @entity2819 pretreatment resulted in development of @entity2072 sensitization, which was absent in sham-pretreated Fischer @entity35 . In contrast, Lewis @entity35 developed @entity2072 sensitization either with or without @entity2819 pretreatment. Thus, both biochemical and behavioral effects of @entity2819 observed in Fischer @entity35 were absent in Lewis @entity35 . We next studied the possibility that certain transcription factors, thought to play a role in @entity669 hydroxylase expression, could be involved in these strain-selective effects of @entity2819 . @entity2819 treatment decreased levels of glucocorticoid receptor immunoreactivity in the ventral tegmental area of Lewis @entity35 , but not of Fischer @entity35 . In addition, drug-naive Fischer @entity35 showed higher ventral tegmental area levels of immunoreactivity of @entity1919 response element binding protein than Lewis @entity35 , with no effect of @entity2819 observed in either strain. These findings suggest that @entity2339 modulation of responses to drugs of abuse is a genetically determined characteristic seen in Fischer @entity35 , but absent in Lewis @entity35 . We propose that @entity2819 administration down-regulates the glucocorticoid receptor in the ventral tegmental area of Lewis @entity35 , and thereby prevents other adaptations to @entity2819 treatment, while in the ventral tegmental area of Fischer @entity35 the lack of glucocorticoid receptor down-regulation and the high basal levels of @entity1919 response element binding protein could facilitate the transcriptional, biochemical and behavioral actions of glucocorticoids.

title: Strain-selective effects of XXXX on locomotor sensitization to @entity2072 and on levels of @entity669 hydroxylase and glucocorticoid receptor in the ventral tegmental area.

entities_list: @entity2819 :: ('MESH:D003345', 'Chemical') :: ['Corticosterone', 'corticosterone']

entities_list: @entity2339 :: ('MESH:D007029', 'Disease') :: ['hypothalamic-pituitary-adrenal axis']

entities_list: @entity1919 :: ('MESH:D000242', 'Chemical') :: ['cyclic AMP']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity2819 :: (MESH:D003345,Chemical) :: ['corticosterone']


abstract: UNASSIGNED: Pay-for-performance (P4P) has been increasingly used across different healthcare settings to incentivize the provision of targeted services. In this study, we investigated the effect of a nationwide P4P scheme for general practitioners implemented in 2012 in France, on cervical @entity5 screening practices. Using data from a nationally representative permanent sample of health insurance beneficiaries, we analyzed smear test use of eligible @entity1 for the years 2006-2014. Our longitudinal sample was an unbalanced panel comprising 180,167 @entity1 eligible from 1 to 9 years each. We took into account that during our study period some @entity1 were exposed to another incentive for screening participation: the implementation in 2010 of @entity347 ( @entity347 ) in a limited number of areas. To evaluate the effect of P4P, we defined three different measures of smear utilization. For each measure, we specified binary panel-data models to estimate annual probabilities and to compare each estimate to the 2011 baseline level. To explore the combined effect of P4P and @entity347 in areas exposed to both incentives, we computed interaction terms between year dummies and area of residence. We found that P4P had a modest positive effect on recommended screening participation. This effect is likely to be transient as annual smear use, both for the whole sample and among @entity1 overdue for screening, increased only in 2013 and decreased again in 2014. The combined effect of P4P and @entity347 on screening participation was not cumulative during the first years of coexistence.

title: Effect of pay-for-performance on cervical XXXX screening participation in France.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity347 :: ('MESH:D019965', 'Disease') :: ['organized screening', 'OS']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: AIM: To review the records of @entity17427 ( @entity17427 ) @entity1 , affected by @entity354 ( @entity354 ), to detect the presence of Barrett's Esophagus (BE). METHODS: A total of 62 @entity17427 @entity1 were investigated for @entity354 (1 month-35 years). In all of them a pH-metry, an @entity1729 with multiple biopsies and a complete radiologic digestive evaluation were carried out. BE was diagnosed in case of replacement of oesophageal mucosa by specialized intestinal-type columnar mucosa. Anti-reflux surgery was considered in case of persistence of BE after medical therapy. Follow-up (mean 3.5 years) consisted in endoscopy every 6 months . RESULTS: @entity354 was found in 50 @entity17427 @entity1 (80%) and BE in six of them (12% of the @entity354 group, 9.6% of the entire population, mean age 17 years, range 6-32 years). A short segment BE was observed in three @entity1 , a long one in two @entity1 and an infiltrating @entity420 of the lower oesophagus in one @entity1 . CONCLUSIONS: A higher frequency of BE in @entity17427 @entity1 than in a normal population is found. A delayed diagnosis because of @entity354 and an altered intestinal motility as a result of @entity16 can be recognized as the main cause.

title: Barrett's esophagus and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity17427 :: ('MESH:D003635', 'Disease') :: ['CDLS', 'Cornelia de Lange Syndrome']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological impairment']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['upper endoscopy']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['atypical GERD symptoms', 'Gastro-oesophageal reflux disease', 'GERD']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity17427 :: (MESH:D003635,Disease) :: ['Cornelia de Lange Syndrome']


abstract: OBJECTIVE: To estimate the prevalence of lymph node involvement in @entity1 with @entity43 . METHODS: A retrospective study was performed of @entity1 with @entity43 evaluated at a single institution between 1985 and 2007. A gynecologic oncology pathologist evaluated all cases. @entity1 with @entity5 of @entity189 metastatic to the ovary from other primary sites were excluded. RESULTS: @entity1 with @entity43 were identified (n=107). All @entity1 underwent primary surgery. At time of surgery, 93 @entity1 (87%) had @entity5 that grossly appeared to be confined to the ovary, and 14 @entity1 (13%) had evidence of @entity66 . Of the 93 @entity1 with @entity5 that grossly appeared to be confined to the ovary at surgical exploration, 51 (55%) underwent lymphadenectomy (n=27 pelvic and paraaortic, n=19 pelvic only, n=5 paraaortic only). Of these 51 @entity1 , none had metastatic disease to the pelvic or paraaortic lymph nodes. In addition, there were no significant differences in progression-free survival and overall survival rates between the @entity1 who underwent lymphadenectomy and those who did not. CONCLUSION: There were no cases of isolated lymph node @entity3 among @entity1 with primary @entity189 grossly confined to the ovary, suggesting that routine lymphadenectomy may be omitted in these @entity1 . LEVEL OF EVIDENCE: III.

title: Prevalence of lymph node @entity3 in primary mucinous XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['primary mucinous ovarian carcinomas']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['extraovarian disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['low malignant potential and mucinous carcinomas', 'mucinous carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity43 :: (MESH:D010051,Disease) :: ['carcinoma of the ovary']


abstract: The results of a 4-week summer camp for @entity28 were reported. Twenty-one @entity1 with moderate to severe @entity28 , aged between 8-13 years, joined the program. Dietary restriction during the official hours and dietary self-control at home were implemented throughout the program. Exercise, swimming and group therapy were also implemented throughout the program. Weekly sight-seeing outside the camp was very interesting for the @entity1 . After the program, all @entity1 had lost weight which was about 5 per cent of their initial weight. Most of the @entity353 was due to loss of body fat but not lean body mass. No complications occurred during the program. The 4-week summer camp is then practical for initiating @entity353 for @entity28 @entity1 . Long-term follow-up which is underway will be reported later.

title: A summer camp for XXXX in Thailand.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'children']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['childhood obesity', 'obese', 'obesity']

answer: @entity28 :: (MESH:D009765,Disease) :: ['childhood obesity']


abstract: AIMS OF THE STUDY AND METHODS: Survival, complications and recurrences after diaphragmatic surgery at primary or interval debulking surgery were compared. One hundred and sixty three consecutive @entity1 with @entity43 underwent diaphragmatic surgery between September 1993 and December 2007. Primary debulking was performed in group 1 (89) @entity1 and interval debulking was performed in group 2 (74) @entity1 . Cytoreductive outcome, @entity1349 ( @entity1349 ), disease-free survival (DFS) and post-operative complications were analysed. RESULTS: Despite differences in baseline mean age (p=0.015), in FIGO stage III/IV (p=0.036) and in mean largest diameter of metastatic disease at the beginning of debulking surgery (p=0.037), the optimal debulking rates ( @entity5 less than 1cm) were similar (p=0.065). Excision of diaphragmatic metastases was most frequently performed in group 1 (77.53%) and coagulation was most frequently performed in group 2 (58.10%). Similar @entity1349 and disease-free survival rates were found. After the propensity matching procedure, the largest diameter of metastatic disease at the time of debulking and no @entity5 (complete debulking) were demonstrated as independent prognostic factors for @entity1349 . Plaque-like lesions on the diaphragm metastases were significantly (p=0.015) more associated with diaphragm recurrence than @entity5720 . Minor and major complications related to diaphragmatic surgery as well as mean operating time, post-operative care in intensive care unit and length of hospitalisation were significantly higher in group 1 rather than in group 2 (p=0.043). CONCLUSIONS: Diaphragmatic dissemination resulted in similar survival and cytoreductive rates after primary and interval debulking. However, the morbidity was less after interval debulking as fewer surgical procedures were performed.

title: Comparison of diaphragmatic surgery at primary or interval debulking in advanced @entity43 : an analysis of 163 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['stage III/IV ovarian cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['residual tumour']

entities_list: @entity5720 :: ('MESH:D007681', 'Disease') :: ['papillary lesions']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Serial @entity400 ( @entity400 ) were used for clinical monitoring of @entity1 liver allografts. Nine liver allograft recipients were monitored with @entity400 at 1-3 day intervals. No complications were recorded. All @entity1 underwent at least 1 inflammatory episode of acute rejection; altogether 11 episodes, all reversible, were recorded. The inflammatory infiltrate consisted mainly of lymphoid cells, including @entity706 , with minor involvement of monocytes, monoblasts, and macrophages. Further analysis of lymphoid cell subpopulations by immunoperoxidase techniques demonstrated an increase of T cells during rejection, both the @entity404 (T4) and @entity405 (T8) subsets were increased. A slight increase of B cells in the graft was also seen. The @entity404 / @entity405 (T4/T8) ratio was first low, peaked at the onset, and decreased toward the end of the episode. No clear correlations to the intragraft cellular events were recorded in corresponding blood specimens. However, an episode of @entity1712 was seen in the blood at the beginning of rejection, correlating with @entity221 in the recipient. Degenerative changes in the parenchymal cells and bile droplets in the hepatocytes, indicating @entity1448 and hepatocyte damage, were seen during all episodes of rejection, and these changes persisted even 10 days after the @entity32 had subsided. The @entity400 -findings correlated well with biochemical laboratory parameters, but the diagnosis of rejection could be established by the @entity400 already 1-5 days earlier than elevated serum values indicated @entity409 .

title: Fine-needle aspiration biopsy in the monitoring of liver allografts. II. Applications to XXXX liver allografts.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoid blasts']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver dysfunction']

entities_list: @entity1448 :: ('MESH:D002779', 'Disease') :: ['cholestasis']

entities_list: @entity400 :: ('MESH:D014202', 'Disease') :: ['fine-needle aspiration biopsies', 'FNAB']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: The current study was designed to explore the antinociceptive, antiinflammatory and antipyretic activity of @entity15384 (PA), isolated from Pistacia integerima bark in various animal paradigms. The results illustrated significant inhibition of noxious stimulation in @entity1543 induced writhing test with maximum effect of 68% at 10mg/kg i.p. In tail immersion test, pretreatment with PA demonstrated marked activity during various assessment times in a dose dependent manner. The maximum @entity158 inhibition was 59.46% at 10mg/kg i.p. after 90min of PA treatment. However, the injection of @entity1510 did not antagonize this induced effect. PA significantly ameliorated post carrageenan induced @entity4 dose dependently during various stages of @entity32 . The effect was most dominant (60.02%) after 3(rd) h of drug administration when examined for 5h. Similarly, it provoked dose dependent antipyretic effect in febrile @entity19 with maximum of 60.04% activity at 10mg/kg i.p. after 3rd hour of PA post treatment. Furthermore, molecular docking was carried out to understand the binding mode of PA. From the docking study it was observed that PA fits well in the active site of @entity10178 enzyme due to @entity3884 and hydrophobic moiety interactions to the important active site of molecule. In conclusion, PA possesses strong peripheral and central antinociceptive activity independent of opioidergic effect which was augmented by its anti-inflammatory and antipyretic activities.

title: In-vivo antinociceptive, anti-inflammatory and antipyretic activity of XXXX isolated from Pistacia integerrima.

entities_list: @entity3884 :: ('MESH:D006859', 'Chemical') :: ['hydrogen']

entities_list: @entity1510 :: ('MESH:D009270', 'Chemical') :: ['naloxone']

entities_list: @entity15384 :: ('MESH:C581170', 'Chemical') :: ['pistagremic acid']

entities_list: @entity1543 :: ('MESH:D019342', 'Chemical') :: ['acetic acid']

answer: @entity15384 :: (MESH:C581170,Chemical) :: ['pistagremic acid']


abstract: PURPOSE: @entity1 with relapsed @entity3052 ( @entity3052 ), who are not eligible for bone marrow transplantation, have a poor prognosis when treated with chemotherapy alone. @entity348 ( @entity348 ) is an effective modality against @entity3052 when used in doses of 1000-1400 cGy with hematopoietic stem cell support. We undertook a phase I study of @entity348 with @entity1261 ( @entity1261 ) support, without stem cell support in @entity1 with @entity3052 either in relapse or second or subsequent remission. METHODS AND MATERIALS: @entity1 with relapsed @entity3052 , or @entity3052 in second or subsequent remission were treated in a phase I study of @entity348 followed by @entity1261 . The first dose level was 200 cGy. After the initial cohort of @entity1 it was clear that @entity1 with @entity1778 did not benefit from this treatment, and subsequent @entity1 were required to be in remission at the time of @entity348 . RESULTS: Eleven @entity1 were treated, 4 in overt relapse, and 7 in remission. 200 cGy was used in all, and dose escalation was not possible due to prolonged @entity882 in all @entity1 but one. Neutrophil recovery was adequate in those @entity1 who remained in remission after @entity348 . @entity1 with @entity1778 had transient reduction in blast counts, but rapid recurrence of their @entity1778 . @entity1 treated in remission had short remissions, with the exception of one @entity1 who is in remission 32 months after treatment. CONCLUSION: There is some antileukemic effect of @entity348 even at 200 cGy, though this dose appears to be too low to help a significant number of @entity1 . If @entity348 is to be escalated without stem cell support, then a thrombopoietic agent will need to be used.

title: Low-dose total body irradiation and @entity1261 without hematopoietic stem cell support in the treatment of relapsed or refractory XXXX ( @entity3052 ), or @entity3052 in second or subsequent remission.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1261 :: ('1440', 'Gene') :: ['granulocyte-colony-stimulating factor', 'G-CSF']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukemia', 'AML']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia', 'overt leukemia']

entities_list: @entity348 :: ('MESH:C535338', 'Disease') :: ['Total body irradiation', 'TBI']

answer: @entity3052 :: (MESH:D015470,Disease) :: ['acute myelogenous leukemia']


abstract: Tissue reaction to biomaterials is dependent on properties such as surface topography. The aim of this study was to evaluate the tissue reaction around implants with different surface topographies. We made coin-shaped @entity1346 and @entity7049 ( @entity15274 ) implants with double-sided parallel microgrooves (depth 1.0 microm; width 10.0 microm) and random roughness on a micrometer scale. The control implants were smooth. These implants were inserted into subcutaneous pockets created on the flanks of @entity1237 . After 1, 3, or 12 weeks, the @entity1237 were sacrificed and the implants retrieved and histologically processed. Light microscopic evaluation revealed the formation of fibrous tissue capsules around all implant materials. The @entity15274 did not visibly degrade during the study period. Histomorphometric analyses were performed on capsule thickness, capsule quality, and on the implant-tissue interface quality. Compared with the @entity1346 implants, the capsules around the @entity15274 implants showed significantly better capsule quality. Compared to the smooth implants, the capsules around the microgrooved implants were thicker, but the capsules around the roughened implants were thinner. However, randomly roughened implant surfaces generally elicited a stronger and more prolonged inflammatory reaction compared to smooth and microgrooved implant surfaces. We conclude that the application of microgrooves or random surface roughness to polymer implants apparently does not have beneficial effects on peri-implant tissue healing.

title: Soft-tissue response to XXXX and @entity7049 implants with a periodic or random surface micropattern.

entities_list: @entity1346 :: ('MESH:D012828', 'Chemical') :: ['silicone']

entities_list: @entity7049 :: ('MESH:C010506', 'Chemical') :: ['poly-L-lactic acid']

answer: @entity1346 :: (MESH:D012828,Chemical) :: ['silicone']


abstract: One hundred and four @entity1 were treated by restorative proctocolectomy with ileal reservoir for @entity31 and @entity1412 . Three different designs of reservoir were used (triple loop 68, double loop 13, quadruple loop 23). There were no postoperative deaths but six (5.8 per cent) had the reservoir removed. Rates for @entity530 were 25, 15 and 13 per cent, and for @entity1321 requiring laparotomy 14.7,0 and 8.6 per cent. Function was assessed in 88 @entity1 (58, 12 and 18) after mean intervals from closure of the ileostomy of 23.7, 12.7 and 4.5 months. Frequency of defaecation per 24 h was 3.7 +/- 1.6, 5.5 +/- 1.6 and 4.1 +/- 1.3, being significantly greater for double loop reservoirs; night evacuation was more prevalent in the same group (26, 58 and 22 per cent). Significantly fewer @entity1 with triple than with double loop reservoirs required antidiarrhoeal medication (19 and 58 per cent). Normal continence occurred in 67, 75 and 89 per cent of @entity1 in the three groups. All @entity1 with double or quadruple loop reservoirs defaecated spontaneously while only 41 per cent with triple loop reservoirs did so. Mean intra-operative reservoir volumes were 177 +/- 64, 172 +/- 58 and 325 +/- 37 ml and volumes after closure of the ileostomy were 416 +/- 176, 197 +/- 69 and 322 +/- 33 ml respectively. Double loop reservoirs were significantly smaller than the other two designs after ileostomy closure. There was an inverse relationship between reservoir volumes and frequency. A quadruple loop reservoir directly connected to the anal sphincter preserved spontaneous evacuation and resulted in function similar to that obtained with the triple loop reservoir.

title: Restorative proctocolectomy with ileal reservoir for XXXX and @entity1412 : a comparison of three reservoir designs.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis']

entities_list: @entity530 :: ('MESH:D010386', 'Disease') :: ['pelvic sepsis']

entities_list: @entity1321 :: ('MESH:D007415', 'Disease') :: ['intestinal obstruction']

entities_list: @entity1412 :: ('MESH:D011125', 'Disease') :: ['familial polyposis']

answer: @entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']


abstract: STUDY OBJECTIVE: To evaluate the odds of achieving viral suppression in @entity1 @entity465 virus (HIV) patients using antiretroviral therapy as a single-tablet regimen (STR) or multiple-tablet regimen (MTR). DESIGN: Retrospective cohort study. DATA SOURCES: South Carolina Medicaid medical and pharmacy paid claims data were obtained from the South Carolina Revenue and Fiscal Affairs Office; laboratory data were obtained from the South Carolina Department of Health and Environmental Control. @entity1 : A total of 1536 @entity1 who were dispensed a complete STR (477 @entity1 ) or MTR (1059 @entity1 ) regimen lasting at least 60 days between January 1, 2006, and December 31, 2013. MEASUREMENTS AND MAIN RESULTS: The analysis examined adherence levels and regimen type on odds of viral load suppression. Regimen adherence levels (90-94%, 85-89%, 80-84%, and less than 80%) were compared with the gold standard adherence for @entity16090 of 95% or greater. @entity1 were followed from index date until the earliest date of regimen discontinuation, treatment switch, end of study period, last date of eligibility, or @entity204 . Differences in outcomes were evaluated by   (2) , Wilcoxon rank sum statistical tests, and multivariate regression models controlling for covariates. For STR regimens we find that, when compared with 95% or greater adherence, there is no statistical difference in the odds of viral suppression with adherence levels greater than or equal to 80%. However, adherence levels greater than or equal to 95% were associated with a greater odds of viral suppression when compared with less than 80% STR adherence (odds ratio [OR] 2.57, Dunnett 95% confidence interval [CI] 1.04-6.32). For MTR regimens, there was no statistical difference in the odds of viral suppression for the adherence level 90-94% compared with the 95% or greater adherence (OR 3.59, Dunnett 95% CI 0.805-16.043). However, the 95% or greater adherence has greater odds of viral suppression compared with all other MTR adherence levels. In addition, no difference was found in the odds of viral suppression between STR and MTR for all adherence levels. CONCLUSIONS: Compared with 95% or greater adherence, STR regimens achieve viral suppression with adherence levels of 80% or greater, whereas MTR regimens require adherence levels of 90% or greater to achieve viral suppression in South Carolina Medicaid @entity1 with @entity16090 / @entity791 .

title: Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in XXXX / @entity791 Patients Receiving Antiretroviral Therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients', 'PATIENTS']

entities_list: @entity465 :: ('MESH:D007153', 'Disease') :: ['immunodeficiency']

answer: @entity16090 :: (11709,Species) :: ['HIV']


abstract: BACKGROUND: Unresectable @entity1419 has a poor prognosis, with a median survival of 5 to 8 months without treatment. Response and survival after chemoembolization were evaluated. METHODS: Lobar or segmental chemoembolization with @entity900 , @entity632 , @entity1138 , @entity4831 , and @entity4832 particles was performed at monthly intervals for 1-4 sessions until the entire @entity5 burden was treated. Cross-sectional imaging and clinical and laboratory evaluation were performed before treatment, 1 month after treatment, and then every 3 months. A second cycle of treatment was performed for intrahepatic recurrence. @entity137 was assessed using NCI CTC v.3.0. Response was evaluated using RECIST criteria, and survival was estimated with Kaplan-Meier analysis. RESULTS: Sixty-two @entity1 were treated. Thirty-seven had pathologically proven @entity201 , and 25 had poorly differentiated @entity420 . One hundred and twenty-two total procedures were performed during the initial cycle of treatment (mean, 2.0 per @entity1 ). Twenty @entity1 received a second cycle, for a total of 165 procedures. There were 5 major complications. Thirty-day disease-specific mortality was 0%. Forty-five of 62 @entity1 were evaluable for morphologic response after completion of their initial cycle: 11% (n = 5) partial responses, 64% (n = 29) stable, and 24% (n = 11) progressed. Median time to progression from first chemoembolization was 8 months, with 28% free of progression at 12 months. Median survival from time of diagnosis was 20 months, with 1-, 2-, and 3-year survival of 75%, 39%, and 17%, respectively. Median survival from time of first chemoembolization was 15 months, with 1-, 2-, and 3-year survival of 61%, 27%, and 8%, respectively. There was no statistically significant difference in survival between @entity1 with @entity201 and those with poorly differentiated @entity420 . @entity1 who also received systemic chemotherapy had improved overall survival (median 28 vs 16 months, P = .02; HR, 1.94; 95% CI, 1.13-3.33). CONCLUSIONS: Chemoembolization provided local disease control (PR + SD) of @entity1419 and @entity420 in 76%. Overall survival after chemoembolization showed the best outcomes for those receiving multidisciplinary integrated liver-directed and systemic therapies.

title: Chemoembolization of XXXX with @entity900 , @entity632 , @entity1138 , @entity4831 , and @entity4832 : a 2-center study.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity']

entities_list: @entity4832 :: ('MESH:D011142', 'Chemical') :: ['polyvinyl alcohol']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['intrahepatic tumor']

entities_list: @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin-C']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatinum']

entities_list: @entity4831 :: ('MESH:D004998', 'Chemical') :: ['ethiodol']

entities_list: @entity1419 :: ('MESH:C535533', 'Disease') :: ['intrahepatic cholangiocarcinoma']

entities_list: @entity201 :: ('MESH:D018281', 'Disease') :: ['cholangiocarcinoma']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma of unknown primary', 'adenocarcinoma of unknown primary, likely cholangiocarcinoma', 'adenocarcinoma']

answer: @entity1419 :: (MESH:C535533,Disease) :: ['intrahepatic cholangiocarcinoma']


abstract: @entity135 is the sixth most common type of @entity5 . @entity286 and @entity285 consumption are implicated in 75% of all SCCHN and have a multiplicative combined effect. It is considered to be the main risk factor for the @entity5 development. The identification of a number of these genetic alterations, for example mutations in the @entity876 @entity5 suppressor gene, paved the way for their use as molecular markers. Mutations in the @entity876 gene frequently occur in many @entity5 and are present in 50-60% of @entity135 , @entity876 plays a sentinel role in the pathways that prevent development of @entity5 by inducing apoptosis, DNA repair and cell cycle arrest in response to different types of cellular stress The aim of the study, was the assessment of the @entity876 mutations prevalence in the @entity135 @entity1 and it's relation with the clinical data and course of the disease. The material comprised of peripheral blood and @entity5 tissue obtained from 50 @entity213 @entity1 with a primary @entity5 in the oral cavity, oropharynx or larynx, who were scheduled for surgical treatment. The mutations in @entity876 , were detected with use of PCR-SSCP technique. In total 8 @entity1 (16%), showed @entity876 mutation in primary @entity5 . The significant correlation between @entity286 and @entity285 consumption and the mutation incidence has been observed. The site of the @entity5 and histopathological grading were also related to the prevalence of mutations, however without reaching the level of statistical significance. There was no correlation between mutations and the T and N stage of the disease.

title: [Analysis of mutations within the @entity876 gene in XXXX with squamous cell carcinoma of the @entity135 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer', 'head and neck cancers', 'Head and neck cancer']

entities_list: @entity286 :: ('4097', 'Species') :: ['tobacco', 'Tobacco']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer', 'tumour']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: This study aims to investigate the influence of the @entity5549 Val(108/158)Met polymorphism on trait and behavioural impulsivity in @entity5550 ( @entity5550 ). @entity5549 Val(108/158)Met has been related to impulsivity in previous studies, but so far no study has investigated the role of this polymorphism in the context of @entity5550 . METHOD: Impulsivity was assessed via a questionnaire (trait) and on a behavioural level via the antisaccade task in a sample of 69 @entity1 classified into one out of three age-matched groups: (1) @entity28 individuals with @entity5550 according to DMS-IV ( @entity5550 +); (2) @entity28 individuals without @entity5550 , matched with the @entity5550 + sample according to body weight (OBED-); and (3) normal-weight healthy controls (NWC). The @entity5549 Val(108/158)Met polymorphism was genotyped in all samples. RESULTS: As expected, the @entity5550 + sample showed higher trait and behavioural impulsivity. Furthermore, within the @entity5550 + group, @entity5549 Met/Met homozygous individuals showed @entity51 in inhibitory control. DISCUSSION: @entity5549 Met/Met homozygous individuals with @entity5550 might represent a specific group in the @entity5550 spectrum, which shows a higher behavioural impulsivity. The association between @entity5549 Val(108/158)Met with inhibitory control should be interpreted with caution because of the small sample size. Larger replication studies are needed to further elucidate the role of the @entity5549 Val(108/158)Met polymorphism in the regulation of @entity1277 . Copyright    2015 John Wiley _ Sons, Ltd and Eating Disorders Association.

title: A Putative Association of XXXX Val(108/158)Met with Impulsivity in Binge @entity1277 .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['stronger deficits']

entities_list: @entity1277 :: ('MESH:D001068', 'Disease') :: ['disordered eating behaviour']

entities_list: @entity5550 :: ('MESH:D056912', 'Disease') :: ['BED', 'binge eating disorder']

answer: @entity5549 :: (1312,Gene) :: ['COMT']


abstract: UNASSIGNED: BACKGROUND Lymph node @entity3 is one of the most important prognostic factors for survival of @entity1 with @entity356 ( @entity356 ) after surgical resection. Nevertheless, a considerable number of @entity1 have node-negative disease. We performed the present systematic review to evaluate survival and identify prognostic factors in node-negative @entity356 @entity1 undergoing curative intent resection. MATERIAL AND METHODS Relevant studies published between January 2000 and January 2015 were identified by searching the PubMed database and reviewed systematically. Summary relative risks (RR) and 95% confidence intervals (95% CI) were estimated using random-effects models. RESULTS Thirty observational studies involving 12 504 @entity1 were included in the review. Median 5-year overall survival was 84.3% (range, 53-96.3%). Pooled analysis showed that old age (RR, 1.26; 95%CI, 1.13-1.42), <D2 lymph node dissection (1.28; 1.05-1.55), larger @entity5 (1.18; 1.10-1.26), serosal invasion (2.03; 1.68-2.44), lymphatic invasion (1.25; 1.00-1.57), vascular invasion (1.67; 1.19-2.34), and lymphovascular invasion (1.93; 1.20-3.10) were significant association with decreased survival. CONCLUSIONS Surgical resection offers good overall survival for @entity1 with node-negative @entity356 . Tumor-related factors seem to have most prognostic significance.

title: Survival after Gastrectomy in Node-Negative XXXX : A Review and Meta-Analysis of Prognostic Factors.

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'GC']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity356 :: (MESH:D013274,Disease) :: ['Gastric Cancer']


abstract: @entity19 sperm contain a major @entity10393 -containing protein of M(r) 95,000 (nonreducing conditions) which has been implicated as a sperm membrane receptor for the egg zona pellucida glycoprotein, @entity11981 (Leyton, L., and Saling, P. (1989) Cell 57, 1123-1130; Leyton, L., LeGuen, P., Bunch, D., and Saling, P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11692-11695). This protein was purified and subjected to limited tryptic digestion and subsequent @entity535 analysis. Three sequenced peptides revealed 100% @entity535 identity to a @entity19 @entity157 hexokinase (Arora, K. K., Fanciulli, M., and Pederson, P. L. (1990) J. Biol. Chem. 265, 6481-6488). The purified protein, which migrated at M(r) 116,000 under reducing conditions (p95/116), reacted with an antiserum to the purified @entity35 brain hexokinase, type 1, and comigrated on @entity3208 - @entity2975 gel electrophoresis with the purified @entity35 brain enzyme under both nonreducing and reducing conditions. Unlike p95/116, the @entity35 brain enzyme was not a @entity10393 -containing protein. The p95/116 protein could be immunoprecipitated with the hexokinase antiserum or an @entity10393 antibody. Limited tryptic digestion of the purified p95/116 and the @entity35 brain enzyme generated subsets of identical peptides which reacted with the hexokinase antiserum. However, p95/116 also contained @entity10393 -containing peptides that were not present in the @entity35 brain hexokinase. When different @entity19 tissues were probed with the hexokinase antiserum all tissues, with the exception of liver, contained immunoreactive protein. In contrast, only sperm and testis possessed a @entity10393 -containing form of hexokinase. These data suggest that the germ cell component of the testis possesses a unique @entity669 -phosphorylated form of hexokinase.

title: p95, the major @entity10393 -containing protein in XXXX spermatozoa, is a hexokinase with unique properties.

entities_list: @entity3208 :: ('MESH:D012967', 'Chemical') :: ['sodium dodecyl sulfate']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity10393 :: ('CHEBI:74956', 'Chemical') :: ['phosphotyrosine', 'O-phosphotyrosine']

entities_list: @entity2975 :: ('CHEBI:51135', 'Chemical') :: ['polyacrylamide']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatoma']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: This study was designed to examine changes in cytochrome P450 17 alpha-hydroxylase (C17) and aromatase (ARO) mRNA contents in the theca layer of preovulatory follicles (POF) as @entity233 hens transit from egg laying to incubation. Hens were grouped into the following categories: 1) laying hens--laid one egg per day and nested 1-2 times per day; 2) transitional hens--laid one egg per day and nested > 4 times per day; and 3) Day 1, Day 3, and Day 5 incubating hens--laid no eggs for 2, 4, or 6 days, respectively, and nested > 4 times per day. Small white follicles (SWF) and the theca layer from the largest (F1) and the third (F3), fifth (F5), and seventh (F7) largest POF were dispersed and challenged with @entity251 (T) for 5 h. Relative levels of C17 and ARO mRNA were examined from the theca layers of F1, F3, F5, F7, and SWF. The number of atretic follicles increased from 0 (layers) to 8 (Day 5 incubating hens). Serum LH, @entity1420 (P), and @entity53 (E), but not T, declined on Day 1 of incubation. Basal levels of P, T, and E from theca and SWF cells declined in incubating hens. Both basal and T-stimulated theca and SWF production of E decreased in incubating hens. C17 and ARO mRNA declined in SWF, F7, and F5 during follicular @entity1146 . It is suggested that reduced gene expression of ovarian steroidogenic enzymes may be a partial determinant of reduced circulating sex @entity134 levels in incubating hens.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Theca cell cytochrome P450 17-hydroxylase and aromatase messenger ribonucleic acid abundance and serum XXXX levels during follicular @entity1146 associated with incubation behavior in the domestic @entity233 hen.

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

answer: @entity134 :: (CHEBI:35341,Chemical) :: ['steroid']


abstract: Proteoglycans (PGs) incorporated into cell layer and secreted into media were characterized during @entity1968 -induced neuronal differentiation of cultured @entity14293 @entity19 @entity189 cells. Heparan @entity597 significantly increased (P < 0.01) in cell layer following neuronal differentiation of @entity14293 cells by 3.9-fold. CL-4B gel chromatography revealed the major PGs present in cell layer of stem cells eluted as a broad peak with a Kav = 0.65, and was susceptible to chondroitin ABC lyase. The chondroitin ABC lyase resistant material eluted as a broad peak between Kav = 0.40 and Kav = 0.60, and was only partially digested with heparitinase/heparinase (with resistant material eluting at Kav = 0.70). Therefore, the cell layer of stem cells contained primarily chondroitin @entity597 /dermatan @entity597 (CS/DS) PGs, with lesser amounts of heparan @entity597 proteoglycans (HSPGs). This was confirmed by @entity214 -PAGE. The CS/DS PGs in the cell layer of stem cells had an apparent M(r) of approximately > 200 kDa, and the HSPGs had an apparent M(r) of approximately 140-230 kDa. In contrast, the major PGs in the cell layer of neurons consisted primarily of HSPGs, with only a minor proportion of CS/DS PGs. Furthermore, both gel filtration chromatography and @entity214 -PAGE analysis revealed a larger HSPG in the cell layer of neurons (Kav = 0.3-0.6 on CL-4B following chondroitin ABC lyase digestion; M(r) 170 kDa- > 400 kDa on @entity214 -PAGE) in comparison to stem cells (Kav = 0.4-0.6 on CL-4B following chondroitin ABC lyase digestion; M(r) 140-230 kDa on @entity214 -PAGE). Likewise, the major PGs secreted into media of stem cells consisted almost exclusively of CS/DS PGs, with lesser amounts of HSPGs, whereas an increase in HSPGs in the media of neurons was apparent. Western, Northern, and immunocytochemical analysis demonstrated that mRNA transcript and protein levels for a specific HSPG (i.e., perlecan) markedly increased in cell layer following @entity14293 neuronal differentiation. Perlecan core protein was identified by Western blot analysis using specific monoclonal and polyclonal antibodies, as a large HSPG with a core protein of apparent M(r) approximately 370-400 kDa, and was observed primarily in extracts from neurons. Northern blot analysis with a cDNA to perlecan revealed a significant (P < 0.01) 12.7-fold increase in expression of perlecan in neurons (day 9) in comparison to stem cells. The increase in perlecan message during @entity14293 neuronal differentiation was concomitant with a significant (P < 0.01) 26.3-fold increase in message for beta-amyloid precursor protein (beta PP).(ABSTRACT TRUNCATED AT 400 WORDS)

title: Characterization of proteoglycans synthesized by @entity19 XXXX cells ( @entity14293 ) reveals increased expression of perlecan (heparan @entity597 proteoglycan) during neuronal differentiation.

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['embryonal carcinoma']

entities_list: @entity1968 :: ('MESH:D014212', 'Chemical') :: ['retinoic acid']

entities_list: @entity597 :: ('CHEBI:16189', 'Chemical') :: ['sulfate']

answer: @entity189 :: (MESH:D002277,Disease) :: ['embryonal carcinoma']


abstract: UNASSIGNED: 4663 Background: Prostate biopsy may not adequately sample small, secondary or tertiary Gleason pattern tumors which can drive clinical outcome. We conducted a study to determine whether @entity5 -derived gene expression profiling could identify a distinct underlying biology associated with clinical recurrence (cR) after radical prostatectomy (RP) across both the primary and highest Gleason pattern (GP) samples. METHODS: All @entity1 (pts) with clinical stage T1/T2 @entity263 treated with RP at Cleveland Clinic from 1987 to 2004 were identified (n~2,600). A cohort sampling design was used to select 127 @entity1 with cR and 374 @entity1 without cR after RP. Each @entity1 had two spatially distinct @entity5 specimens sampled that included the primary GP (PGP) and the highest GP (HGP). @entity1412 and clinical data were centrally reviewed. RNA was extracted from 6 manually dissected 10  m fixed paraffin embedded tissue sections obtained from the @entity5 specimens and expression of 732 @entity5 -related and reference genes was quantified using RT-PCR. Clinical recurrence-free interval (cRFI) and @entity263 -specific survival (PCSS) were analyzed using Cox PH regression. RESULTS: Blocks from 441 @entity1 were evaluable. Median F/U was 5.8 years. Pts were mostly Caucasian (83%), clinical stage T1 (66%), had baseline PSA <10 ng/mL (82%), and surgical GS <= 7 (87%). We identified 235 genes associated with cRFI in both the PGP and HGP samples, well in excess of the number expected by chance. 75% of these genes were also associated with PCSS. Many genes remained significantly associated with cRFI in multivariate analyses adjusted for pathologic T-stage, GS, AUA risk group and CAPRA score (221, 99, 244, and 271 genes respectively). CONCLUSIONS: Gene expression analysis using quantitative RT-PCR identified a large number of genes, and underlying biology, that are strongly associated with clinical recurrence in both the primary and the highest Gleason pattern that adds prognostic value beyond clinical and pathology covariates.

title: Quantitative gene expression in primary and highest Gleason pattern @entity5 specimens identifies genes associated with clinical recurrence and XXXX -specific survival after radical prostatectomy.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'RP tumor', 'cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1412 :: ('MESH:D011125', 'Disease') :: ['Surgical GS']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: BACKGROUND: @entity311 during pregnancy remains a serious public health problem, with substantial risks for the mother, her foetus and the newborn. The aim of this study was to determine the prevalence of @entity311 and possible risk factors for @entity281 among pregnant @entity1 in a semi-urban area in north-western Nigeria. Pregnant @entity1 are among the most susceptible to @entity281 . Knowledge of their @entity281 status is an important yardstick to measure the effectiveness of any @entity311 control programme. METHODS: We conducted a cross sectional study in the semi-urban area of Argungu, Kebbi State Nigeria. Two hundred and fifty five pregnant @entity1 were included in the study after informed verbal consent was obtained. For each @entity1 , the socio-demographic profile, stage of pregnancy and attitude to the use of insecticide- treated nets (ITNs) were investigated using a questionnaire. Peripheral blood samples were collected and thick blood smears were prepared and stained with Giemsa stains to check for @entity311 . The associations between age, education level and use of ITNs with occurrence of @entity281 during pregnancy were analysed using the chi-square test. RESULTS: One hundred and six (41.6%) out of 255 pregnant @entity1 were infected with @entity311 parasites, with a mean parasite density of 800 parasites l(-1). It was found that prevalence and parasite density decreased as age increased. The chi-square test indicated that a lack of education and non-usage of ITNs were significantly associated with @entity281 . CONCLUSION: @entity311 is still a major public health issue among pregnant @entity1 mainly due to illiteracy and non -compliance to using ITNs. Increasing awareness about @entity311 preventive measures and early attendance of antenatal care services will help to reduce @entity311 and, consequently, its associated morbidities and mortalities.

title: Prevalence and risk factors associated with XXXX among pregnant @entity1 in a semi-urban community of north-western Nigeria.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'participant']

entities_list: @entity311 :: ('MESH:D008288', 'Disease') :: ['Malaria', 'malaria parasitaemia', 'malaria']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['malaria infection']

answer: @entity281 :: (MESH:D007239,Disease) :: ['malaria infection']


abstract: Effective therapy for @entity1 with @entity1459 or evolving @entity583 following coronary bypass surgery requires accurate delineation of the pathoanatomy and prompt intervention. We therefore performed cardiac catheterization in 10 consecutive @entity1 : four with @entity583 and six with refractory @entity1459 (NYHA class IV). All @entity1 with @entity583 were found to have completely thrombosed vein grafts supplying totally occluded native coronary arteries. In three @entity1 with evolving @entity583 occurring within 4 weeks of coronary bypass surgery, graft @entity715 was caused by venous valves in two @entity1 and a suboptimal @entity254 in a third. The fourth @entity1 sustained a @entity583 7 years after coronary bypass surgery with @entity731 causing vein graft @entity715 . Therapy with intragraft streptokinase resulted in complete clearing of @entity715 , @entity158 relief, and control of injury current in all four @entity1 . @entity1459 with concomitant ST and T wave changes occurred in six @entity1 . In two @entity1 symptoms occurred early (within 6 months), whereas @entity951 developed 4 to 10 years after coronary bypass graft surgery in four @entity1 . In the two @entity1 with early recurrence of symptoms suboptimal @entity254 was found in one, while the other @entity1 had a venous valve in the vein graft in conjunction with a @entity850 in the native coronary artery. In three of four @entity1 with late recurrence of @entity951 , symptoms developed as a result of @entity731 in their vein grafts; in the fourth @entity1 an occluded graft was found to supply a stenosed native coronary artery.(ABSTRACT TRUNCATED AT 250 WORDS)

title: XXXX and evolving @entity583 following coronary bypass surgery: pathogenesis and treatment with interventional catheterization.

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'acute myocardial infarction']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic stenosis', 'atherosclerotic plaque rupture']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity1459 :: ('MESH:D000789', 'Disease') :: ['Rest angina', 'unstable angina']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombus']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity1459 :: (MESH:D000789,Disease) :: ['Unstable angina']


abstract: This study examined the relationship between @entity25 and the course of @entity148 in primary care @entity1 . @entity1 were part of the Primary Care Anxiety Project (PCAP), a naturalistic, longitudinal study of @entity148 in primary care. @entity1 completed an intake evaluation and follow-up assessments at 6 months, 12 months, and annually thereafter. Only @entity1 with sleep data at intake were included in the current study (n=533). The majority (74%) reported experiencing @entity25 at intake. Those with a diagnosis of @entity148 ( @entity148 ) or @entity1005 ( @entity1005 ) were over 2 times more likely to have sleep problems. @entity25 at intake did not relate to the longitudinal course of @entity148 , @entity913 , @entity4697 , or @entity3119 . However, it did predict the course of @entity1005 , controlling for comorbid @entity308 ( @entity308 ) and having more than one @entity148 diagnosis intake, those with @entity25 at intake being less likely to remit from @entity1005 in the 5 years of follow-up. By year 5, only 34% of those with sleep problems at intake remitted from @entity1005 whereas 56% of those without @entity25 remitted from the disorder. The findings suggest that @entity25 in @entity1005 may have prognostic significance and may be important to address in clinical interventions.

title: The relationship between @entity25 and the course of XXXX in primary care @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'Participants']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['MDD', 'major depressive disorder']

entities_list: @entity4697 :: ('MESH:D016584', 'Disease') :: ['panic disorder']

entities_list: @entity913 :: ('MESH:D010698', 'Disease') :: ['social phobia']

entities_list: @entity1005 :: ('MESH:D013313', 'Disease') :: ['post-traumatic stress disorder', 'PTSD']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['GAD', 'anxiety disorder', 'generalized anxiety disorder', 'anxiety disorders']

entities_list: @entity3119 :: ('MESH:D009771', 'Disease') :: ['obsessive-compulsive disorder']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disturbance', 'Sleep disturbance']

answer: @entity148 :: (MESH:D001008,Disease) :: ['anxiety disorders']


abstract: BACKGROUND AND PURPOSE: In hemiparetic individuals, low endurance to exercise may compound the increased energy cost of movement and contribute to poor rehabilitation outcomes. The purpose of this investigation was to describe how @entity64 @entity1 responded to intense exercise and aerobic training. METHODS: Forty-two subjects were randomly assigned to an exercise training group or to a control group. Treatments were given three times per week for 10 weeks in similar laboratory settings. Baseline and posttest measurements were made of maximal @entity26 consumption, heart rate, workload, exercise time, @entity551 , and sensorimotor function. RESULTS: Only experimental subjects showed significant improvement in maximal @entity26 consumption, workload, and exercise time. Improvement in sensorimotor function was significantly related to the improvement in aerobic capacity. After treatment, experimental subjects showed significantly lower systolic blood pressure at submaximal workloads during the graded exercise test. CONCLUSIONS: We conclude that @entity64 @entity1 may improve their aerobic capacity and submaximal exercise systolic blood pressure response with training. Sensorimotor improvement is related to the improvement in aerobic capacity.

title: Physiological outcomes of aerobic exercise training in @entity64 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['resting and submaximal blood pressures']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['hemiparetic stroke']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Although @entity4501 and @entity1152 ( @entity10859 -EA) are surgically correctable, late @entity1576 have been reported. We administered a respiratory and gastrointestinal symptom questionnaire and performed standard pulmonary function tests (PF T's) and @entity2710 challenge testing on an unselected group of 25 subjects with @entity10859 -EA who underwent surgery at our institution between 1963 and 1985. Results were compared to predicted normals, as well as 10 sibling controls. While the mean values of lung function test results for the @entity10859 -EA group were within the normal range, they were significantly different from their siblings. Thirteen of the 25 @entity10859 -EA group (52%), but none (0%) of the controls, had @entity358 . This was classified as restrictive in 9 (36%), obstructive in 3 (12%), and mixed in 1. In addition, @entity1224 [defined as a positive @entity2710 challenge (PC20 < or = 8 mg/mL)], was found in 6 of 18 @entity10859 -EA subjects and 4 of the 9 controls who were evaluated. Comparison of @entity10859 -EA subjects with normal and abnormal PFTs showed no difference in the incidence of @entity825 , @entity3332 or dilatation, recurrent @entity55 , or @entity354 . The respiratory symptom score in the subjects and controls was similar, and did not correlate with @entity358 . The cause of the @entity358 remains unexplained.

title: Late pulmonary function following repair of XXXX or @entity1152 .

entities_list: @entity825 :: ('MESH:D055090', 'Disease') :: ['tracheomalacia']

entities_list: @entity3332 :: ('MESH:D004940', 'Disease') :: ['esophageal strictures']

entities_list: @entity4501 :: ('MESH:D014138', 'Disease') :: ['tracheoesophageal fistula']

entities_list: @entity1152 :: ('MESH:D004933', 'Disease') :: ['esophageal atresia']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonias']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['abnormal pulmonary function', 'pulmonary function abnormalities']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory complications']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophageal reflux']

entities_list: @entity2710 :: ('MESH:D016210', 'Chemical') :: ['methacholine']

entities_list: @entity1224 :: ('MESH:D000402', 'Disease') :: ['airway hyperreactivity']

answer: @entity4501 :: (MESH:D014138,Disease) :: ['tracheoesophageal fistula']


abstract: BACKGROUND: Cytochrome P450 aromatase (encoded by the @entity4819 /aromatase gene) plays a critical physiologic role in @entity46 . @entity2449 is known to suppress @entity1421 ( @entity1421 )-induced @entity4819 messenger RNA (mRNA) expression in @entity1 endometriotic stromal cells (ESCs). However, the possible mechanism behind this suppression remains to be determined. METHODS: In this study, ESCs were cultured with @entity2449 , @entity1421 , and @entity860 ( @entity8582 )-activated protein kinase (AMPK) inhibitors. Expression of @entity4819 mRNA and aromatase activity were measured by quantitative polymerase chain reaction and aromatase activity assay, respectively. The binding of the @entity1919 response element-binding ( @entity10366 ) protein to @entity4819 promoter II (PII) was assessed by chromatin immunoprecipitation assay. RESULTS: We demonstrated that @entity2449 downregulated the expression of aromatase mRNA (32%) and activity (25%) stimulated by @entity1421 (4.18-fold and 2.14-fold) in ESCs via stimulation of AMPK. Following @entity1421 treatment, there was a marked increase in @entity10366 binding to aromatase PII, while @entity2449 attenuated the above-mentioned stimulation by 67%. CONCLUSION: @entity2449 could inhibit @entity1421 -induced @entity4819 mRNA expression and aromatase activity via AMPK activation and inhibition of @entity10366 to @entity4819 PII in @entity1 ESCs. The results of the present study suggest that @entity2449 may have unique therapeutic potential as an antiendometriotic drug in the future.

title: XXXX Suppresses @entity1421 -Induced Cytochrome P450 Aromatase Gene Expression and Activity via Stimulation of @entity8582 -Activated Protein Kinase in @entity1 Endometriotic Stromal Cells.

entities_list: @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2', 'prostaglandin E2']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

entities_list: @entity1919 :: ('MESH:D000242', 'Chemical') :: ['cyclic AMP']

entities_list: @entity860 :: ('MESH:D000249', 'Chemical') :: ['adenosine monophosphate']

entities_list: @entity2449 :: ('MESH:D008687', 'Chemical') :: ['Metformin', 'metformin']

answer: @entity2449 :: (MESH:D008687,Chemical) :: ['Metformin']


abstract: BACKGROUND: The elderly population is large in general and growing due to advancement of health care education. These @entity1 are faced with numerous physical, psychological and social role changes that challenge their sense of self and capacity to live happily. Many @entity1 experience loneliness and @entity308 in old age, either as a result of living alone or due to lack of close family ties and reduced connections with their culture of origin, which results in an inability to actively participate in the community activities. With advancing age, it is inevitable that @entity1 lose connection with their friendship networks and that they find it more difficult to initiate new friendships and to belong to new networks. The present study was conducted to investigate the relationships among @entity308 , loneliness and sociability in elderly @entity1 . MATERIALS AND METHODS: This study was carried out on 55 elderly @entity1 (both @entity1 and @entity1 ). The tools used were Beck Depression Inventory, UCLA Loneliness Scale and Sociability Scale by Eysenck. RESULTS: Results revealed a significant relationship between @entity308 and loneliness. CONCLUSION: Most of the elderly @entity1 were found to be average in the dimension of sociability and preferred remaining engaged in social interactions. The implications of the study are discussed in the article.

title: Loneliness, XXXX and sociability in old age.

entities_list: @entity1 :: ('9606', 'Species') :: ['people', 'women', 'men']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depression']


abstract: PURPOSE: To study the clinical and radiologic findings in 15 @entity1 presenting with both @entity600 and @entity2477 and to determine which lesions caused the acute clinical symptoms. METHODS: Lesions were infratentorial in 7 @entity1 and supratentorial in 7 other @entity1 . In one @entity1 the @entity600 was infratentorial and the @entity2477 supratentorial. In all 15 @entity1 clinical examination and CT were performed. In 10 @entity1 MR was performed at the time of the initial CT scan. In 5 @entity1 only late MR is available. RESULTS: Acute clinical signs were present in 9 @entity1 ( @entity302 , @entity1158 , meningeal signs, @entity129 ). On CT the @entity2477 was missed in 9 @entity1 , in 6 @entity1 because of acute @entity548 . On MR the @entity2477 was missed in 1 of 2 cases with acute @entity548 but seen in all other @entity1 . On repeat MR all @entity2477 were correctly identified. On CT, 11 @entity600 were seen. On MR all @entity600 were seen. CONCLUSIONS: The frequent association of @entity600 and @entity2477 is confirmed. MR is superior to CT in the detection of both @entity2477 and @entity600 . Furthermore our data support the hypothesis that @entity2477 and not the @entity600 cause the acute clinical symptoms because of @entity548 .

title: Simultaneous occurrence of @entity600 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1158 :: ('MESH:D006429', 'Disease') :: ['hemiplegia']

entities_list: @entity129 :: ('MESH:D003389', 'Disease') :: ['cranial nerve deficit']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['developmental venous anomalies', 'developmental venous anomaly']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity2477 :: ('MESH:D006392', 'Disease') :: ['cavernous angiomas', 'cavernous angioma']

answer: @entity2477 :: (MESH:D006392,Disease) :: ['cavernous angiomas']


abstract: BACKGROUND: Control of blood pressure is a key component of @entity65 prevention, but is difficult to achieve and until recently has been the sole preserve of health professionals. This study assessed whether self-management by @entity1 with poorly controlled @entity101 resulted in better blood pressure control compared with usual care. METHODS: This randomised controlled trial was undertaken in 24 general practices in the UK. @entity1 aged 35-85 years were eligible for enrolment if they had blood pressure more than 140/90 mm Hg despite antihypertensive treatment and were willing to self-manage their @entity101 . @entity1 were randomly assigned in a 1:1 ratio to self-management, consisting of self-monitoring of blood pressure and self-titration of antihypertensive drugs, combined with telemonitoring of home blood pressure measurements or to usual care. Randomisation was done by use of a central web-based system and was stratified by general practice with minimisation for sex, baseline systolic blood pressure, and presence or absence of @entity2316 . Neither @entity1 nor investigators were masked to group assignment. The primary endpoint was change in mean systolic blood pressure between baseline and each follow-up point (6 months and 12 months). All randomised @entity1 who attended follow-up visits at 6 months and 12 months and had complete data for the primary outcome were included in the analysis, without imputation for missing data. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN17585681. FINDINGS: 527 @entity1 were randomly assigned to self-management (n=263) or control (n=264), of whom 480 (91%; self-management, n=234; control, n=246) were included in the primary analysis. Mean systolic blood pressure decreased by 12.9 mm Hg (95% CI 10.4-15.5) from baseline to 6 months in the self-management group and by 9.2 mm Hg (6.7-11.8) in the control group (difference between groups 3.7 mm Hg, 0.8-6.6; p=0.013). From baseline to 12 months, systolic blood pressure decreased by 17.6 mm Hg (14.9-20.3) in the self-management group and by 12.2 mm Hg (9.5-14.9) in the control group (difference between groups 5.4 mm Hg, 2.4-8.5; p=0.0004). Frequency of most side-effects did not differ between groups, apart from leg swelling (self-management, 74 @entity1 [32%]; control, 55 @entity1 [22%]; p=0.022). INTERPRETATION: Self-management of @entity101 in combination with telemonitoring of blood pressure measurements represents an important new addition to control of @entity101 in primary care. FUNDING: Department of Health Policy Research Programme, National Coordinating Centre for Research Capacity Development, and Midlands Research Practices Consortium.

title: Telemonitoring and self-management in the control of XXXX (TASMINH2): a randomised controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients', 'Participants', 'people']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetes or chronic kidney disease']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: Influence of @entity10699 and @entity2165 on the balance between the sympathetic and parasympathetic nervous systems was evaluated in 8 @entity101 subjects by spectral analysis of @entity551 (BP). Before and after administration of either @entity10699 (n = 7) or @entity2165 (n = 7) for 2 weeks, BP was continuously and non-invasively monitored by a finger-cuff manometry (Finapres). A time series of instantaneous HR was constructed from the BP signal. A time series of mean BP was also constructed. Spectral analysis was performed by the use of an autoregressive algorithm on these time series (approximately 180 sec). Each spectrum was subdivided into low-(0.05-0.15 Hz, LF) and high-frequency (0.15-0.4 Hz, HF) components, and each component was divided by the sum of the two for normalization. As a measure of the balance between the sympathetic and parasympathetic nervous systems, the ratio of LF to HF (LF/HF) was evaluated. @entity10699 increased fractional HF in the HR spectrum from 0.45 +/- 0.12 to 0.73 +/- 0.08 (p < 0.01) and decreased fractional LF from 0.55 +/- 0.12 to 0.27 +/- 0.08 (p < 0.01); consequently, it decreased LF/HF from 1.4 +/- 0.5 to 0.4 +/- 0.2 (p < 0.01). @entity2165 had similar effects on these parameters. Neither of these beta-adrenergic blockades produced a discernible decrease in LF/HF in the BP spectrum. In conclusion, these beta-adrenergic blockades decreased LF/HF in the HR spectrum in @entity101 subjects, which suggests that they improved the balance between the sympathetic and parasympathetic nervous systems.

title: Influence of XXXX on heart rate spectrum in @entity101 subjects.

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['heart rate (HR) and systemic blood pressure']

entities_list: @entity10699 :: ('MESH:C024523', 'Chemical') :: ['Arotinolol', 'arotinolol hydrochloride', 'arotinolol']

entities_list: @entity2165 :: ('MESH:D001262', 'Chemical') :: ['Atenolol', 'atenolol']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

answer: @entity10699 :: (MESH:C024523,Chemical) :: ['arotinolol hydrochloride']


abstract: Chronic Immune Dysschwannian/Dysneuronal @entity305 is an @entity1897 known to usually respond to intravenous immunoglobulin-G treatment. Benefit can involve any combination of motor-nerve fibers and large and small sensory-nerve fibers responsible for a progressively crippling, unbalancing, discomforting or @entity2531 . " @entity3949 " is commonly considered untreatable. However, 81% of my 48 recently-summarized type-2 @entity6 @entity1 with @entity305 , adequately-treated with intravenous immunoglobulin-G, off-label, were relieved, sometimes completely, of various motor and sensory symptoms, including @entity158 , thereby resembling Chronic Immune Dysschwannian/Dysneuronal @entity305 . Spinal fluid protein in them is often elevated, higher values seeming to auger a better intravenous immunoglobulin-G response. Continuing the improvement requires continuing the intravenous immunoglobulin-G treatment, indicating both intravenous immunoglobulin-G responsiveness and dependency. The intravenous immunoglobulin-G responsive type-2 @entity3949 usually is dysschwannian, sometimes mainly dysneuronal intravenous immunoglobulin-G, the most beneficial and safest treatment, is costly, but if intravenous immunoglobulin-G-treatability of a dysimmune component of @entity3949 is overlooked, dismissed or rejected, as commonly happens, other costs are high regarding the @entity1 's worsening morbidity and disability, and resultant need for increased medical care. A novel intravenous immunoglobulin-G regimen effective for fragile @entity1 is Two Non-Consecutive-Days Every Week, using 0.4 gm/kg body wt/day. Possible molecular mechanisms of intravenous immunoglobulin-G benefit are discussed. I propose that a) there is a higher incidence of Chronic Immune Dysschwannian/Dysneuronal @entity305 -like @entity16 in type-2 @entity6 @entity1 and in @entity1 with a strong family history of type-2 @entity6 , and b) the intravenous immunoglobulin-G-treatable @entity16 in type-2 @entity6 can be brought on by the genetico-diabetoid-2 state. The genetic-metabolic milieu (but not necessarily @entity413 dysmetabolism per se.) of type-2 @entity6 putatively predisposes to the presumably-dysimmune intravenous immunoglobulin-G-responsive @entity305 . In some of our @entity1 , especially ones having a strong type-2 @entity6 genetic background, the intravenous immunoglobulin-G-responsive @entity16 preceded the diagnosis of type-2 @entity6 by 5-10 years. Accordingly, Chronic Immune Dysschwannian/Dysneuronal @entity305 @entity1 having a strong type-2 @entity6 genetic background are designated "genetico- @entity16 " prior to their manifesting type-2 @entity6 . Intravenous immunoglobulin-G is herein suggested as a treatment for @entity6185 , a recent, and feared-repetitive, pandemic with many fatalities caused by a highly-contagious mutant coronavirus, for which there is no definitive treatment. Intravenous immunoglobulin-G might: a) combat a dysimmune component of @entity6185 , including the reactive cytokine-chemokine storm against respiratory tissues; b) contain some antibodies effective against the coronavirus non-specific components of @entity6185 ; c) block host-cell receptors for the virus; and d) counteract secondary infections.

title: Intravenous immunoglobulin G is remarkably beneficial in chronic immune dysschwannian/dysneuronal polyneuropathy, XXXX , and potentially in severe @entity6185 .

entities_list: @entity6185 :: ('MESH:D045169', 'Disease') :: ['Severe Acute Respiratory Syndrome']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['diabetoid-2 neuropathy', 'neuropathy']

entities_list: @entity3949 :: ('MESH:D003929', 'Disease') :: ['diabetes polyneuropathy', 'type-2 diabetes neuropathy', 'Diabetic neuropathy']

entities_list: @entity305 :: ('MESH:D011115', 'Disease') :: ['polyneuropathy', 'Polyneuropathy']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['autoimmune peripheral-nerve and/or nerve-root disorder']

entities_list: @entity2531 :: ('MESH:D013001', 'Disease') :: ['painful disorder']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity3949 :: (MESH:D003929,Disease) :: ['diabetes-2 neuropathy']


abstract: BACKGROUND AND OBJECTIVE: Dissociative experiences are widespread among @entity1 with @entity4697 and have a negative impact on cognitive-behavioural therapy. In this study we aimed to investigate whether or not dissociative experiences affect response to drug treatment for @entity4697 . METHODS: Thirty-five @entity1 , 20 @entity1 and 15 @entity1 , with a mean age of 35.4 years and a diagnosis of @entity4697 , were enrolled in the study. @entity903 20 mg/day was administered over 6 weeks. @entity1 were assessed on the @entity4785 ( @entity4785 ) and @entity4697 and @entity8396 Scale (PAS) at the commencement of therapy, and on the PAS again after therapy. RESULTS: The average @entity4785 score was determined as 30.3. @entity8396 was identified in 34.3% of @entity1 . @entity4785 scores were higher in @entity1 with @entity8396 than in those without @entity8396 . @entity8396 scores were higher in @entity1 with high @entity4785 scores. When @entity1 were divided into those with low @entity4785 scores (< or =30) and those with high @entity4785 scores (>30), a decrease in PAS scores with treatment was observed in both groups, but the decrease was greater in those with low @entity4785 scores (18.8 +/- 6.8 vs 5.7 +/- 5.7 in the high- @entity4785 score group; Z = 4.486, p = 0.00000053). Similarly, while a decrease in PAS scores with treatment was observed both in @entity1 with @entity8396 (p < 0.05) and in those without @entity8396 , PAS scores decreased more in non-agoraphobic @entity1 (16.7 +/- 7.5 vs 4.8 +/- 6.6 in @entity1 with @entity8396 ; Z = 3.799, p = 0.000047). In addition, the decrease in PAS scores was significantly correlated with baseline @entity4785 score (beta = 0.706, T = 5.727, p = 0.0000022). CONCLUSION: This study shows that dissociative experiences reduce the response to drug therapy in @entity1 with @entity4697 .

title: Effect of dissociative experiences on drug treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity4697 :: ('MESH:D016584', 'Disease') :: ['Panic', 'panic disorder']

entities_list: @entity4785 :: ('MESH:D004213', 'Disease') :: ['DES', 'Dissociative Experience Scale']

entities_list: @entity8396 :: ('MESH:D000379', 'Disease') :: ['Agoraphobia', 'agoraphobia']

entities_list: @entity903 :: ('MESH:D017374', 'Chemical') :: ['Paroxetine']

answer: @entity4697 :: (MESH:D016584,Disease) :: ['panic disorder']


abstract: OBJECTIVE: To examine the prognostic difference in well-differentiated @entity259 between macroscopic extrathyroidal extension (ETE), which is appreciated in the operating room, vs microscopic ETE, which is only appreciated under the microscope by the pathologist. DESIGN: Retrospective medical record review. SETTING: Tertiary care academic hospital. @entity1 : Among 582 @entity1 , those who were surgically treated for stage III well-differentiated @entity259 with a minimum 5-year follow-up were included. Fifty-five @entity1 (10%) (17 males and 38 females [mean age, 53.1 years]) met the selection criteria. MAIN OUTCOME MEASURES: Disease-specific survival and overall survival. RESULTS: Thirty-two @entity1 (58%) had macroscopic ETE, while 23 @entity1 (42%) had microscopic ETE. Twenty-year disease-specific survival in the macroscopic group was 47% (8 of 17) and 45% (5 of 11) in the microscopic group (P=.45). Twenty-year overall survival in the macroscopic group was 27% (3 of 11) and 24% (4 of 17) in the microscopic group (P=.59). The only confounding factor was external beam radiation therapy (EBRT). More @entity1 with macroscopic ETE were treated with EBRT (P=.007). When survival was stratified according to EBRT, @entity1 with macroscopic ETE who did not receive EBRT had diminished disease-specific survival (P=.07) and overall survival (P=.12). On multivariate analysis, EBRT was the only predictor of improved disease-specific survival (P=.02) and overall survival (P=.06). CONCLUSIONS: In selected @entity1 with macroscopic ETE, we recommend postoperative EBRT. Further investigation is required to determine whether macroscopic ETE vs microscopic ETE is an independent predictor of outcome.

title: Extrathyroidal extension in well-differentiated XXXX : macroscopic vs microscopic as a predictor of outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS', 'patients']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer']

answer: @entity259 :: (MESH:D013964,Disease) :: ['thyroid cancer']


abstract: @entity65 continues to be the principal cause of @entity204 in Western countries. Epidemiological studies have repeatedly demonstrated a striking relationship between blood pressure and the risk of @entity65 in that those with the highest levels of blood pressure are at the greatest risk for subsequent disease or @entity204 . However, most blood pressure-related @entity65 occur at much lower levels of blood pressure. Any attempt to substantially reduce the frequency of blood pressure-related @entity65 mandates treatment of large numbers of asymptomatic subjects who are, on average, only exposed to a slight increase in risk. Based on current demographic trends, this requirement will become even more striking in the future. Non-pharmacological interventions provide the most attractive approach to the prevention and treatment of @entity101 . However, the efficacy and acceptability of long term non-drug treatment is uncertain. Drug treatment remains the best proven and fundamental approach to the treatment of established @entity101 . Based on the lifelong nature of antihypertensive therapy and the changing risk profile of those being treated, a desire to recognise and prevent adverse effects of antihypertensive drug administration is now more important than ever. Special care is essential during the treatment of uncomplicated mild @entity101 with few or no other cardiovascular risk factors.

title: Epidemiological considerations in the treatment of XXXX .

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensives', 'high blood pressure', 'hypertension']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['Cardiovascular disease', 'cardiovascular disease', 'cardiovascular complications']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']